FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Late clinical · capacity Advancing MariTide Phase 3 trials for weight management and expanding Phase 3 recruitment for cardiovascular disease, heart failure and sleep apnea Also seen: Commercial · sales

  • The company reported progress in the MARITIME-1 and MARITIME-2 Phase 3 trials and recruitment for Phase 3 trials related to cardiovascular disease, heart failure and sleep apnea. Source
  • The company reported a 9% year-on-year increase in second-quarter drug sales. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Medical & MSL

Companies at the same stage and their people flow →

← Company library
United States / Company briefSources checked 2026-10-03

Amgen

Official name · Amgen Inc.

Develops and markets biologic medicines across disease areas and advances obesity and metabolic candidates.

MariTide / maridebart cafraglutide

Phase 3

Reported ongoing MARITIME-1 and MARITIME-2 phase 3 studies for weight management.

Progress reported

Reported enrollment in MariTide phase 3 studies covering cardiovascular outcomes, heart failure and sleep apnea.

Individual vacancy

Inflammation Research - In Vivo Pharmacology Scientist

Recheck current availability

Observed 2026-10-03

Work
Conducts in vivo inflammation and autoimmune disease model studies, ex vivo assays and cross-functional work.
Experience & requirements
Basic Qualifications lists a doctorate, or a related master’s plus 2 years in biotech/pharma, or a bachelor’s plus 4 years. The body requires rodent, cellular/biochemical assay and multicolor flow-cytometry experience.
Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. Amgen Reports Second Quarter 2026 Financial Results ↗Amgen · Published 2026-08-04 · Sources checked 2026-10-03
  2. Inflammation Research - In Vivo Pharmacology Scientist ↗Amgen · Published 2026-09-17 · Sources checked 2026-10-03